tirzepatide off fda shortage list news october 18 2025 has announced that the of # tirzepatide, the ingredient in FDA says the Zepbound shortage

Any cloudiness, visible particles, or unexpected discoloration means the medication may have degraded

Eden Healths GLP-1 program is currently paused for new patients

Related Comparisons Semaglutide vs Tirzepatide Research indicates that Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates superior weight loss efficacy compared to Semaglutide, a GLP-1-only agonist, in head-to-head clinical trials

Proper storage and refrigeration prevents most degradation issues

The choice of which GLP-1 is best for diabetes treatment will depend on factors like patient preference with injection frequency, individual tolerance of potential side effects, overall effectiveness in managing blood sugar levels, and insurance coverage

Survodutide side effects (Phase 2 data) Nausea: 56% of participants Vomiting: 27% Diarrhea: 22% Constipation: 21% Discontinuation due to adverse events: 24.6% Serious adverse events: 4.2% In the MASH trial, rates were even higher: nausea 66%, diarrhea 49%, vomiting 41%